Shares of METIS TECHBIO-P (07666) experienced a significant rise of over 7% during the morning trading session. At the time of writing, the stock was up 7.58%, trading at HK$14.25 with a turnover of HK$1.78 million.

The upward movement follows the company's recent announcement of a strategic alliance with Deerfield, a premier global health investment and innovation platform. Under this partnership, Deerfield will engage in extensive collaboration with METIS TECHBIO-P concerning its proprietary AI-powered nano-delivery platform, NanoForge, its associated solution portfolio, and key pipeline projects. The focus will be on global clinical development and commercial expansion initiatives.

The NanoForge platform is reported to have established a comprehensive framework that integrates AI-driven protein generation, in vivo delivery technologies, and the development of next-generation immunotherapies. A key component, the AiProtein platform, is designed for the rapid discovery and optimization of novel therapeutic proteins. This includes T-cell engagers (TCEs), in vivo protein therapies, and other advanced immunomodulatory treatment modalities.

The strategic alliance is intended to deeply integrate METIS TECHBIO-P's proprietary and differentiated technologies in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's extensive industry experience and specialized capabilities in translational medicine, clinical development, healthcare innovation, and global partnerships.